doxylamine

Small moleculeapproved

Approved

Apr 7, 1948

Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic. Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects. Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women. — NCATS

Clinical trial activity

10 trials · 21 clinical orgs · 19 marketing orgs

Phase 1
3
Phase 2
3
Phase 3
2
Phase 4
1

Earliest trial started Jan 1, 2008 (NCT00614445)

Timeline

1940s

  1. Apr 7, 1948

    Earliest FDA Approval

  2. Apr 7, 1948

    Sanofi-Aventis — NDA Secondary Org

1970s

  1. Feb 13, 1978

    Chattem — NDA Secondary Org

1980s

  1. Oct 8, 1985

    Copley Pharmaceuticals — Marketing Organization

1990s

  1. Sep 18, 1996

    Perrigo — Marketing Organization

2000s

  1. Aug 27, 2004

    LNK International — Marketing Organization

  2. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2008

    Duchesnay Inc. — Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Apr 8, 2013

    Duchesnay Inc. — Marketing Organization

  3. Apr 8, 2013

    Duchesnay Inc. — NDA Secondary Org

  4. Aug 19, 2016

    Actavis — Marketing Organization

  5. Aug 19, 2016

    Allergan PLC (2015) — Marketing Organization

  6. Dec 6, 2017

    Par Pharmaceuticals — Marketing Organization

  7. Dec 6, 2017

    Endo Pharmaceuticals — Marketing Organization

  8. Dec 6, 2017

    Bristol-Myers Squibb — Marketing Organization

  9. Dec 6, 2017

    PH HEALTH — Marketing Organization

2020s

  1. Jul 6, 2020

    Mylan — Marketing Organization

  2. Jul 6, 2020

    PHARMOBEDIENT — Marketing Organization

  3. Mar 1, 2022

    AbbVie — Marketing Organization

  4. Aug 4, 2023

    Bionpharma Inc — Marketing Organization

Indications

Mechanism of action

Combination products

  • bendectin

    with pyridoxine

    Also known as bonjesta, diclegis

Approval history

  • approvedApr 7, 1948

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCOC(C)(C1=CC=CC=C1)C2=CC=CC=N2
Mol. weight
270.3694 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Over the Counter

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine
  • 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine
  • 2-dimethylaminoethoxyphenylmethyl-2-picoline
  • 2-dimethylaminoethoxyphenylmethyl-2-picoline
  • decapryn
  • decapryn
  • decapryn
  • dossilamina
  • dossilamina
  • doxilamina
  • doxilamina
  • doxilminio
  • doxilminio
  • doxylamine
  • doxylamine
  • doxylamine
  • doxylamine
  • doxylamine
  • doxylamine
  • doxylamine
  • doxylamine
  • doxylamine
  • doxylamine
  • doxylamine
  • (+/-)-doxylamine
  • doxylamine succinate
  • doxylamine succinate
  • doxylamine succinate
  • doxylamine succinate
  • doxylamine succinate
  • doxylaminum
  • doxylaminum
  • doxy-sleep-aid
  • doxy-sleep-aid
  • n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine
  • n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine
  • phenyl-2-pyridylmethyl-beta-n,n-dimethylaminoethyl ether
  • phenyl-2-pyridylmethyl-beta-n,n-dimethylaminoethyl ether
  • unisom
  • unisom

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06772974N/AJan 15, 2025Nawaz Sharif Medical College, University of Gujarat
NCT06342778Phase 1Feb 27, 2024Valenta Pharm JSC
NCT05498233N/AJul 11, 2022Valenta Pharm JSC
NCT04401384N/AJun 1, 2020Harbin maternal and child health care hospital, Hegang maternal and child health care hospital, Heilongjiang University of Traditional Chinese Medicine, Jiamusi maternal and child health care hospital, Jixi maternal and child health care hospital, Mudanjiang maternal and child health care hospital
NCT03905564Phase 1Jun 30, 2019Grunenthal
NCT03017430Phase 4Jan 1, 2014St. Petersburg Bekhterev Research Psychoneurological Institute
NCT01243437Phase 2Dec 1, 2010Centers for Disease Control and Prevention (CDC), Government of Uganda, Medical Research Council
NCT00857987Phase 3Apr 1, 2010Azidus
NCT00796315Phase 1Dec 1, 2008Consumer Healthcare Products Association, Procter and Gamble
NCT00614445Phase 3Jan 1, 2008Duchesnay Inc., Premier Research Group, The University of Texas, Dallas, University of Toronto
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (21)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Valenta Pharm JSCFor profit2222022
AzidusFor profit1112010
Centers for Disease Control and Prevention (CDC)Government1112010
Consumer Healthcare Products AssociationAcademic/Hospital1012008
Duchesnay Inc.For profit1112008
Government of UgandaGovernment1012010
GrunenthalFor profit1112019
Harbin maternal and child health care hospitalAcademic/Hospital1012020
Hegang maternal and child health care hospitalAcademic/Hospital1012020
Heilongjiang University of Traditional Chinese MedicineAcademic/Hospital1112020
Jiamusi maternal and child health care hospitalAcademic/Hospital1012020
Jixi maternal and child health care hospitalAcademic/Hospital1012020
Medical Research CouncilGovernment1012010
Mudanjiang maternal and child health care hospitalAcademic/Hospital1012020
Nawaz Sharif Medical CollegeAcademic/Hospital1112025
Premier Research GroupFor profit1012008
Procter and GambleFor profit1112008
St. Petersburg Bekhterev Research Psychoneurological InstituteAcademic/Hospital1112014
The University of Texas, DallasAcademic/Hospital1012008
University of GujaratAcademic/Hospital1012025
21 organizations
Page 1 / 2

Marketing (20)

OrganizationOrg typeRelationshipDate
AbbVieFor profitMKTGMar 1, 2022
ActavisFor profitMKTGAug 19, 2016
Allergan PLC (2015)For profitMKTGAug 19, 2016
Bionpharma IncFor profitMKTGAug 4, 2023
Bristol-Myers SquibbFor profitMKTGDec 6, 2017
ChattemFor profitNDA2Feb 13, 1978
Copley PharmaceuticalsFor profitMKTGOct 8, 1985
Duchesnay Inc.For profitMKTGApr 8, 2013
Duchesnay Inc.For profitNDA2Apr 8, 2013
Endo PharmaceuticalsFor profitMKTGDec 6, 2017
LNK InternationalFor profitMKTGAug 27, 2004
MylanFor profitMKTGJul 6, 2020
PH HEALTHFor profitMKTGDec 6, 2017
PHARMOBEDIENTFor profitMKTGJul 6, 2020
Par PharmaceuticalsFor profitMKTGDec 6, 2017
PerrigoFor profitMKTGSep 18, 1996
PfizerFor profitNDA2
Quantum PharmaceuticalFor profitMKTG
Richardson Vicks IncFor profitNDA
Sanofi-AventisFor profitNDA2Apr 7, 1948